Can you take Daunorubicin with Sorafenib?

DAUNOrubicin has a major potential interaction with Bleeding Disorder.

Daunorubicin hydrochloride is a potent bone marrow suppressant. Suppression will occur in all patients given a therapeutic dose of the drug. Therapy with daunorubicin hydrochloride should not be started in patients with preexisting drug-induced bone marrow suppression unless the benefit from such treatment warrants the risk. Persistent, severe myelosuppression may result in superinfection or hemorrhage. Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding. Close clinical monitory of hematopoietic function is recommended.

DAUNOrubicin has a major potential interaction with Bone Marrow Depression/Low Blood Counts.

Daunorubicin hydrochloride is a potent bone marrow suppressant. Suppression will occur in all patients given a therapeutic dose of the drug. Therapy with daunorubicin hydrochloride should not be started in patients with preexisting drug-induced bone marrow suppression unless the benefit from such treatment warrants the risk. Persistent, severe myelosuppression may result in superinfection or hemorrhage. Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding. Close clinical monitory of hematopoietic function is recommended.

DAUNOrubicin has a major potential interaction with Fever.

Daunorubicin hydrochloride is a potent bone marrow suppressant. Suppression will occur in all patients given a therapeutic dose of the drug. Therapy with daunorubicin hydrochloride should not be started in patients with preexisting drug-induced bone marrow suppression unless the benefit from such treatment warrants the risk. Persistent, severe myelosuppression may result in superinfection or hemorrhage. Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding. Close clinical monitory of hematopoietic function is recommended.

DAUNOrubicin has a major potential interaction with Heart Failure.

Daunorubicin can cause myocardial toxicity leading to congestive heart failure. Patients with preexisting heart disease or prior anthracycline therapy are at increased risk of congestive heart failure. The benefit-to-risk ratio of daunorubicin therapy in such patients should be weighed before starting treatment. The incidence of drug-induced congestive heart failure in adults is increased when the total cumulative dose of daunorubicin exceeds 550/mg/m2. An electrocardiogram and/or determination of systolic ejection fraction prior to each course of therapy is recommended.

DAUNOrubicin has a major potential interaction with Infection.

Daunorubicin can induce severe myelosuppression at therapeutic doses. The use of daunorubicin may be contraindicated in patients with known infectious diseases. All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during therapy with daunorubicin. Close clinical monitoring of hematopoietic function is recommended.

SORAfenib has a moderate potential interaction with Interstitial Lung Disease.

The use of certain multikinase inhibitors has been associated with pulmonary toxicity. Serious cases of interstitial lung disease (ILD), including fatal cases and interstitial pneumonitis or pulmonary fibrosis have been reported. Caution is recommended when using these agents in patients with a history of interstitial pneumonitis or pulmonary fibrosis or those patients presenting with acute onset of new or progressive unexplained pulmonary symptoms such as dyspnea, cough, and fever pending diagnostic evaluation. If ILD is confirmed, these agents should be permanently discontinued and appropriate measures should be instituted. Treatment should be immediately withheld in patients diagnosed with ILD/pneumonitis and permanently discontinued if no other potential causes of ILD/pneumonitis have been identified.

DAUNOrubicin has a moderate potential interaction with Liver Disease.

Daunorubicin is extensively metabolized to a biologically active form within normal erythrocytes and leukocytes. Further metabolism via reduction and conjugation has been demonstrated. Approximately 40% of daunorubicin is eliminated in an active form by biliary excretion. Patients with hepatic impairment may be at increased risk for toxicity. Therapy with daunorubicin should be administered cautiously and the dosage reduced in patients with compromised hepatic function. Clinical evaluation of liver function prior to each course of treatment with daunorubicin is recommended.

SORAfenib has a moderate potential interaction with Pulmonary Impairment.

The use of certain multikinase inhibitors has been associated with pulmonary toxicity. Serious cases of interstitial lung disease (ILD), including fatal cases and interstitial pneumonitis or pulmonary fibrosis have been reported. Caution is recommended when using these agents in patients with a history of interstitial pneumonitis or pulmonary fibrosis or those patients presenting with acute onset of new or progressive unexplained pulmonary symptoms such as dyspnea, cough, and fever pending diagnostic evaluation. If ILD is confirmed, these agents should be permanently discontinued and appropriate measures should be instituted. Treatment should be immediately withheld in patients diagnosed with ILD/pneumonitis and permanently discontinued if no other potential causes of ILD/pneumonitis have been identified.

DAUNOrubicin has a moderate potential interaction with Renal Dysfunction.

Approximately 25% of daunorubicin is eliminated in an active form in the urine. Patient with renal impairment are at risk of greater toxicity noted at the recommended dose of daunorubicin. Therapy with daunorubicin should be administered cautiously and at a reduced dosage in patients with significantly compromised renal function. Clinical evaluation of renal function prior to each course of treatment is recommended.